Open House - Global Healthcare 2022: Scandion Oncology | Edison Group
Scandion Oncology was established to address one of the most important problems in modern oncology: the treatment of cancers that have developed resistance to chemotherapy.
-
Bo Rode Hansen, CEO, Scandion
Bo Rode Hansen, President & CEO of Scandion Oncology, has more than two decades’ leadership experience in the global biotech and pharmaceutical industry, having served in several executive leader positions and on boards. Bo has extensive experience throughout the value chain of the life-science business including General Management, Research & Development, Business Development, Financing and Merger & Acquisitions. He holds a MSc in biochemistry and a PhD in Pharmaceutical Sciences, both from Copenhagen University, and an executive MBA from Henley Business School. Prior to joining Scandion Oncology in 2020, Bo served as the CEO & founding President of RNA therapeutics company Genevant Sciences in Cambridge, MA, USA. Previously, he was the General Manager of Roche Innovation Center Copenhagen. He also served as Global Head of RNA Therapeutics at Roche pRED in Basel, CH. Prior to that, Bo was an Executive in Santaris Pharma, a Danish RNA therapeutics company, which was acquired by F. Hoffmann-La Roche in 2014. He joined Santaris at the foundation of the company in 2003 and held different positions, including as an executive and VP, Drug Discovery & Alliance.
